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Abstract Parent companies usually undertake corporate 
spin-offs to cope with higher competitive environments 
or when, in high technology industries, the differences 
between R&D investments and intangible assets are 
larger. Consistent with the recent “positive view”, spin-
offs can be considered as a “proactive strategic choice” 
to foster innovation, develop new activities, being 
different from past strategic initiatives and, more 
generally, not being strictly connected to the corporate 
strategy of the firm. In order to investigate the relation 
between divestiture decisions and innovation, we 
conduct an explorative case study in the pharmaceutical 
industry to show how spin-offs can help firms to explore 
new opportunities for innovation, search for new funding 
and push to create the basis for future development. 
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1. Introduction  
 
In recent years, divestiture activities have grown 
substantially worldwide. The volume and value of 
divestiture transactions increased until the end of 2009, 
reaching a record of 12,000 transactions, experiencing a 
global increase of 15% compared to 2005 (Deloitte, 2010).  
Corporate divestiture is a major mechanism used by 
firms to streamline and refocus their businesses. It 
represents a firm adjusting its portfolio structure [1], 
which occurs when a firm spins off, carves out or sells off 
a business [2,3].  
 
Strategy scholars have portrayed divestiture as a 
multidimensional and complex event, which may 
critically affect a firm’s performance [4,5].  
 
Moreover, the international literature suggests that large 
and established firms experience problems in conducting 
new and more efficient innovative processes, because 
they are subject to organizational inertia and perceive 
unexplored patterns as highly risky [6]. On the contrary, 
small organizations are less constrained by organizational 
structure. Through the acquisition, assimilation and 
exploitation of firm-specific knowledge [7], small and 
medium enterprises, in fact, are more prone to commit 
different resources to new and hazardous processes of 
innovation; their “boldness” is often productive, since 
they have been found to achieve greater levels of 
innovation than large companies [8]. 
 
Established firms can usually support poor innovation 
through a reconfiguration of their resources, by 
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acquiring, removing or retaining assets [9,10]. 
Additionally, the empirical research suggests that large 
firms can improve poor innovation through a 
reconfiguration of their resources, by acquiring, removing 
or retaining assets [9-12]. In this area of studies, there is 
some evidence that large companies take advantage of 
divestitures, by benefiting from the innovation carried 
out within small and more “entrepreneurial” divested 
units. This is consistent with the recent “positive view” of 
divestiture [13,14], according to which, divesting is not 
necessarily a corrective action, carried out to remedy past 
strategic mistakes, but it can also be a “proactive strategic 
choice”, aimed at pursuing precise productive objectives. 
 
The paper is thus organized as follows. We firstly review 
the literature on the relation between divestiture and 
innovation, with a focus on the impact of spin-off 
decisions. Secondly, we develop a theoretical model that 
investigates how the innovation strategy of firms is 
affected by divestiture decisions. To do so, we conduct an 
exploratory case study to show how and when 
innovation drivers can influence a firm’s decision to 
divest. Finally, in the last section of the paper, we draw 
some conclusions and implications. 
 
2. Literature review: divestiture and innovation 
 
Innovation activities usually stem from a reconfiguration 
of the available resources. In fact, innovation comes from 
those active and creative processes which redesign the 
internal and external boundaries of the firm, through the 
acquisition, the disposal, and maintenance of its 
resources. In other words, the process of resource 
reconfiguration can be viewed as a way to identify new 
innovative opportunities through a process of building, 
borrowing, and buying [15].  
 
Among all the practicable strategies to boost a 
reconfiguration process, divestures are becoming a 
fruitful perspective [13, 15, 16]. Recent evidence, indeed, 
has shown that firms often divest their businesses but 
they maintain a relation with them and eventually 
consider reacquiring them at a later point [13]. Divested 
firms are able to push forward with innovation activities 
as a response to new opportunities. In this perspective, 
the proactive view of divestiture [17] underlines the 
existence of a positive effect of divesture on innovation. 
Indeed, the achievement of innovation outcomes depends 
on the availability of managerial resources to be invested 
in innovation processes. In sum: the greater the attention 
paid by a firm’s management, the higher the results 
obtained by the innovation activities will be. By contrast, 
“overloaded” managers may pay less attention to the 
innovative process. In fact, time is one of the most salient 
constraints on managerial behaviour. Managers have to 
concentrate on many tasks simultaneously, thus a 
selection process can occur in managerial behaviour. In 
this framework, divestures, viewed as a way by which to 
increase managerial resources, can be seen as a way to 
foster innovation inside the firm [17]. 
 
To sum up, this perspective suggests that the level of 
innovation of a firm increases with a divesture operation. 
Furthermore, when the divesture is a part of a greater 
reconfiguration of a firm’s activities, it is reasonable to 
expect a direct and positive relation between the decision 
- taken on a business as a whole - and the R&D activities 
developed by that business. Thus, if divestures are 
implemented to release some resources to be invested in 
new opportunities, the cumulative and path-dependent 
nature of the innovative capabilities will address these 
resources towards technology areas of expertise already 
developed by the firm.  
 
2.1 Spin-off decisions and innovation  
 
A firm undertakes a divesture operation whenever it has 
to sell or spin-off a division, a business unit, a product 
line or a subsidiary in order to offer it on the market as a 
new and independent firm [4]. 
 
Traditionally, divestures have been seen as financing 
operations or instruments used to gain a higher 
organizational efficiency, even through the correction of 
previous strategic decisions that may have become 
irrelevant for the firm [18]. Nevertheless, over the last 
years, a new perspective has emerged looking at 
divestures as a proactive choice [19, 11, 16] useful for 
launching new entrepreneurial initiatives or supporting 
the growth, the creation of value in and, in some cases, 
the survival of the parent company [14]. 
 
These considerations are a suitable basis to start 
investigating the main features and characteristics of a 
corporate spin-off operation. This analysis will serve as a 
preliminary to the study of the relationship between 
divestures, executed through the spin-off mode, and the 
innovation process.  
 
Parent companies usually undertake corporate spin-offs to 
cope with higher competitive environments or when, in 
high technology industries, the differences between R&D 
investments and intangible assets are larger. Moreover, 
divesture operations seem to be a profitable tool to be used 
when the market underestimates the firm due to its 
organizational structure; for a review see [14]. Frequently, 
firms decide to divest a business unit through a spin-off 
operation when its resources and competencies are really 
valuable, but their management, under the parent 
company control, leads to a lower efficiency [19, 18]. This is 
consistent with previous studies [20] that suggest how 
spin-offed business units are generally represented by 
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profitable activities that, after the divesture process, can 
grow more rapidly than others. In fact, through the spin-off 
operation, the business unit becomes an independent firm 
and its shares are distributed pro-quota to the shareholders 
of the parent company [4]. 
 
Therefore, the decision to spin-off a business unit is 
connected to the choice of maintaining a connection 
between the parent company and the spin-off unit [13]. In 
fact, by acting in this way, the latter can profit from the 
support of the parent company in terms of resources, 
activities and knowledge. At the same time, the parent 
company lays the foundation to one day profit from the 
future development of the spin-off unit. The final effect of 
this process is a reverse phenomenon by which the single 
unit starts to support the parent company [21].  
 
The idea that spin-offs can be the best instrument to 
explore new contexts is supported by the consideration 
that this form of divesture can help the firm in finding a 
good trade-off between the risks connected to the 
exploration of new opportunities and the exploitation of 
existing ones, in which the firm can continue to operate. 
This consideration can be analysed also from a cultural 
point of view. For example, the unit can be equipped with 
a new management with an entrepreneurial style of 
leadership useful to cope with new markets, while the 
parent company can maintain its managers and their 
style of management.  
 
Furthermore, the international literature has shown how 
divestures can be used as a means to research and explore 
new settings beyond the traditional competencies of the 
company [13]. In this way, firms can invest in high-tech 
and/or R&D projects. Divesture operations, in fact, allow 
companies to reduce risks. Moreover, they allow the spin-
off unit to compete as an independent firm in the new 
competitive environment. In sum, prominent companies 
can decide to employ spin-off operations to develop new 
activities, different from past strategic initiatives and, 
more generally, not strictly connected to the corporate 
strategy of the firm.  
 
Additionally, the parent company can be interested in 
those resources that can provide it with precious 
synergies within the whole portfolio structure. In this 
perspective, spin-offs can be effective instruments to 
expand firm’s competencies and capabilities to discover 
new synergies. This is the reason why parent companies 
usually continue to collaborate with the spin-off unit even 
after the divesture. This collaboration can lead toward the 
allocation of resources from the parent company to the 
spin-off unit or the sharing of knowledge and networks 
between the two firms. In this way, the collaborative 
relationship will influence the development of innovation 
positively [16]. 
Moreover, the unit could be the ideal space for 
developing innovation activities. Indeed, innovation 
stems from informal and decentralized structures where 
the diffusion of knowledge is wide, the hierarchical levels 
are few and the bureaucracy is low. The decentralization 
process provides the single unit with more managerial 
autonomy and control of resources, letting managers 
commit to more innovative projects.  
 
Small firms, characterized by simple structures, can adapt 
themselves promptly to changes in the environment, due 
to the fact that they are closer to the market and they 
obtain information about new opportunities quickly. 
Besides, business relationships are easier to exploit and 
manage in small firms through their different functions. 
Usually, the units divested through a spin-off have a 
simple and decentralized structure; they are not often 
diversified and they are always focalized on a particular 
business. 
 
3. A case study 
 
Recent works [20] have shown a clear linkage between 
innovation efforts and performance in high-tech 
companies in Italy. In particular, they found a strong and 
positive correlation between innovation-related variables 
(e.g., innovation efforts, innovation protection, risk 
propensity) and firm performance. Starting from this 
evidence, in our case study, we investigate how spin-off 
decisions can improve innovation efforts and, as a 
consequence, can increase a firm’s performance. 
Specifically, in order to investigate the relation between 
divestiture decisions and innovation, we conducted an 
explorative case study on one of the main firms operating 
in the Italian pharmaceutical industry. 
 
For reasons of privacy we call this firm Alpha Pharma. 
Alpha Pharma is structured into three main business 
units: i) manufacturing, ii) marketing and sales, and iii) 
international markets. 
 
The manufacturing business unit acts both as a business 
captive, providing the marketing and sales unit with the 
finished products, and as a supplier for third parties. 
 
The marketing and sales unit is focused on the placement 
and selling of pharmaceutical goods on the Italian 
market, and managing a customer portfolio, composed of 
wholesalers, pharmacies, and hospitals.  
 
Finally, the third business unit is the outcome of the 
internationalization strategy developed by Alpha Pharma 
through a two-step process: firstly, the firm has been 
focusing on the exports opportunities achieved by 
licensing out agreements with international partners, 
whereby 20% of its total turnover is now abroad; 
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secondly, in the near future, some branches will be 
opened in target countries to sell products with property 
trademarks. 
 
As far as innovation and development activities are 
concerned, Alpha Pharma’s business model is based 
mainly on two specific activities: 
• The line extension of the product portfolio, driven by 
innovation to develop new pharmaceutical solutions 
in line with the level of compliance required and 
expected by patients;   
• Licensing in for specific medicines to complete the 
therapeutic fields in which Alpha Pharma acts 
through international networking activities. 
Companies with potentially successful medicines, 
which are in the development process and that are 
looking for retailers in Italy, are contacted in order 
to create different types of relations (licenses, sales 
concessions, etc.). 
 
Actually, Alpha Pharma was born with a different 
business model, mainly focused on research activities as 
its corporate mission rather than commercial activities 
[22]. This mission was once conducted by the Research 
and Development Business Unit, at a research centre 
located in the north of Italy, and later it was the object of 
a spin-off operation. 
 
3.1 The development process 
 
As previously mentioned, Alpha Pharma’s mission, 
implemented through its R&D Business Unit, was based 
on controlling the entire process of developing the 
medicine. To understand the complexity and the 
ambitiousness of the goal, we propose a brief description 
of the process’s contents and of its critical aspects.  
 
The development process of a medicine from the 
generation of its molecule, provided with pharmaceutical 
properties, until its allocation in the market is, nowadays, 
very long and complex. The long period required depends 
on the numerous activities that have to take place and on 
their variety. These activities, even if similar from a 
molecular point of view, present each time their own 
uniqueness linked to the specific substance and its 
therapeutic aims, and a high complexity due to the number 
of competences, specializations and professions that are 
involved. In fact, scientists from different cultures, such as 
biologists, chemicals, bioinformatics, pharmacologists, 
toxicologists, pathologists, clinicians, patent specialists, and 
specialists in industrial production have to interact, 
exploiting the synergies and the opportunities coming 
from collaboration with other experts acting inside and 
outside the boundaries of the firm. This means establishing 
and managing relationships with people from hospitals, 
clinics, university laboratories, and so on. 
The entire process, from the molecule to its patent, can 
last up to 12 years. Even if we look at the time to market 
only, this period lasts no less than 10 years. Empirical 
evidence shows that, during recent decades, these lead 
times seem to increase due to the higher complexity 
connected to the pharmaceutical industry.  
 
This consideration, combined with the short length of 
patents’ legal protection (20 years) and the increasing cost 
of research, raises the risks associated with research 
activities.  
 
In short, the entire process is characterized by a reduction 
in incoming cash flows, more and more uncertainty, and 
by an extension of outgoing cash flows. This makes it 
mandatory for sponsoring companies to constantly 
monitor all the steps of the development, especially those 
related to longer times and higher costs. 
 
Taking into account the high investments required by the 
process of research and development, together with the 
uncertainty characterizing this kind of activities, it is 
important to set some systems of control and some 
managerial capabilities to manage human and 
professional resources acting inside the firm or working 
with it. 
 
To achieve this, the entire process is structured in 
sequential phases, each of them with specific targets to be 
reached. Each phase leads to an output which is to be 
critically analysed in order to decide whether to proceed 
or not with the following steps. According to this method, 
it is possible to identify seven different phases. 
 
The first one, the discovery, ends with the identification 
of a molecule with specific pharmaceutical characteristics. 
This molecule is usually named the leader. In the second 
step, called preclinical, the leader is tested with animals, 
from toxicological, pharmacokinetic and medicinally 
dynamic points of view, to check its efficacy and security 
and to define a hypothetic dose for humans. With the 
third step, phase I, the experimentation starts to evaluate 
the tolerability, bioavailability and other pharmacokinetic 
and medicine dynamic parameters of the medicine on 
healthy humans. The next phase is the clinical 
development, which involves testing the product on a 
limited number of patients affected by the disease for 
which the medicine has been studied. This step, called 
phase II, aims to identify the right, efficient dose.  
 
The next phase – phase III – calls for some clinical studies 
in different centres of research to conduct an analysis on a 
number of patients large enough to prove the efficacy of 
the medicine. After this phase has passed the process of 
patenting and the launch on the market will start. 
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3.2 The crisis of the R&D-based business model 
 
R&D activities conducted by Alpha Pharma are guided 
by the aim of studying medical needs not yet satisfied by 
other firms. Even if Alpha Pharma has always worked on 
the osteoarticular field of study, during recent years, the 
research centre has focused its attention towards 
innovative areas not aligned with the core competencies 
of the firm, such as oncology and the study of the central 
nervous system. To conduct effective research in these 
contexts, some agreements with prestigious international 
private and public centres of research have been signed, 
building a project portfolio of more than 20 initiatives. 
 
In establishing these partnerships and developing these 
projects, Alpha Pharma invested more than 100 million 
Euros in the last 10 years. This led to the development of 
a sort of research atmosphere that, in turn, influenced the 
mission of the firm and its culture at every organizational 
level. Acting in this way, Alpha Pharma improved its 
positioning in the market, increasing its brand awareness 
and reputation as a research company. 
 
The complexity of the management of the process of 
medicine development both on a purely scientific level and 
from the point of view of the financial implications have 
imposed a clear afterthought in the strategic mission: the 
substantial likelihood of the failure of the investments 
needed to carry forward the research pipeline, even in the 
final stages of development, has been considered a factor 
that is extremely risky, particularly for a company of 
medium size. To cope with this problem, since 2009, Alpha 
Pharma decided to streamline its research pipeline, 
focusing on oncology and turning to venture capitalists to 
fund the research and increase the attractiveness of its 
projects for potential industry partners. 
 
Nevertheless, the participation of venture capital or 
private equity firms led to the entry of a new 
management component into the corporate structure. 
 
Alpha Pharma, being a wealthy company from an 
economic point of view, had the option to decide to not 
allow a private equity investor to enter its capital, 
considering that it would have had a considerable 
influence in the decision making processes concerning the 
whole company, not only the development process. 
 
This and other considerations led to the birth of Beta 
Research.  
 
3.3 The spin-off: BETA Research 
 
Beta Research was founded in July 2011, as a spin-off of 
the Research Division of Alpha Pharma. Beta, despite 
being an independent company, is still part of the 
Holding Company, which also controls Alpha Pharma, 
which, in turns, owns the 100% of Beta Research.  
 
The spin-off put together a research centre, with 
researchers who had previously worked at Alpha Pharma 
and intellectual property rights developed on research 
projects. It is equipped with a proper management team 
to achieve its economic objectives and it can profit from a 
very prestigious international scientific board to support 
the development of research projects.  
 
The research activities of Beta Research are mainly focused 
on the development of a biotechnology platform in 
addition to the development of its research pipeline, for 
which it is seeking a financial and industrial partnership. 
 
Moreover, Beta Research is still involved in the 
management of the Alpha Pharma pipeline support, 
which provides legal counselling and development in 
laboratories on approved projects.  
 
In order to achieve growth and development goals, firms 
acting in the pharmaceutical industry need stability to 
make them less vulnerable to the risk of issues arising 
from the research field. At this stage, the revenue growth 
is entrusted to national and international brokers, 
however, Beta’s research participation at major events is 
expected to spread the production capacity and the 
company's “know-how” in the area of oncology research. 
 
Alpha Pharma had a very ambitious objective: to move 
from its traditional field of research (the osteoarticular field 
of study) towards new areas, such as oncology and the 
central nervous system. Osteoporosis and cardiovascular 
gills are satisfied markets where the physicians and the 
patients currently have a sufficient supply of drugs 
available. On the contrary, in oncology and central nervous 
system pathologies, there is still a lot to be investigated. 
Starting from this simple consideration, Alpha Pharma 
launched a research programme conducted by one of its 
business unit. Notwithstanding the huge amount of 
resources invested over the years, the research activities in 
these fields of study did not produce satisfying results. To 
cope with this situation and recover the lost efficiency, the 
management of the firm decided to spin-off the research 
activities, creating a new structure with: on the one side 
Alpha Pharma with two divisions -  marketing & sales and 
manufacturing - focusing more on the traditional markets 
and activities in which Alpha Pharma was and still is 
strong from a commercial point of view; on the other side 
the division of R&D named Beta Research, focusing on the 
development of a technology platform in the field of cell 
therapy, mainly used for oncology research. 
 
The Beta Research spin-off was also born to create a 
vehicle in which the needs of the finance company could 
be reconciled with those of the financial market.  
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Furthermore, the creation of Beta Research allowed Alpha 
Pharma to solve another problem connected to its 
positioning in the pharmaceutical industry. In fact, Alpha 
Pharma is known as a company specialized in the 
osteoarticular field. The presence of a bundle of activities 
in the area of cell therapy inside the boundaries of the 
firm could generate perplexity among stakeholders and 
scepticism and disorientation among other actors 
(especially partners and customers) acting in the same 
industry. 
 
The creation of a spin-off has allowed the company to 
launch a new society specialized in the development of 
products in oncology. To strengthen the image of the new 
firm, a scientific board, made up of specialist scientists, 
was nominated to guide the research activities.  
 
Finally, from a strategic planning point of view, the birth 
of Beta Research, even with all the uncertainties related to 
a start-up biotech company, seems to have put together 
the puzzle in terms of greater entrepreneurial and 
innovative logic. It is still too early to say whether Beta 
Research will have a history of success and if innovation 
obtained and proposed will develop a concrete business 
key, but it certainly possible to say that Alpha Pharma, 
despite having invested heavily in R&D, was not very 
likely the most appropriate vehicle to ensure the success 
of their business activities in biotech research. However, 
the company has already registered some positive results: 
revenues and the EBITDA show a significant increase 
after the spin-off. Specifically, in the last three years, 
revenues moved from 68 to 101 million Euros, while the 
EBITDA presents in the same period a CAGR of 32.6% 
proving a strong recovery of efficiency inside the 
company. 
 
4. Conclusion 
 
The relationship between spin-offs and innovation is of 
particular interest and relevance. A review of the 
literature and an analysis of possible implications in 
terms of the innovative performance of the decision to 
spin-off reveals how spin-offs can actually encourage 
innovative performance. Specifically, we conduct an 
explorative case study to show how a spin-off can help 
firms to explore new opportunities for innovation, search 
new funding and push for the creation of the basis for 
future development and innovation. 
 
The results of this study have two primary implications 
for theory and practice regarding the role of divestiture in 
innovation. 
 
First, moving forward from the work of [13] and in line 
with recent studies emphasizing the importance of post-
divestiture linkages between parent and divested units 
[23], we have extended previous work by focusing on the 
innovation activities of divested units and analysing the 
design and outcome of a spin-off decision. 
 
Second, our preliminary results are consistent with a 
positive view of divestiture [13]. Accordingly, 
divestiture is viewed not just as a result of a firm’s 
failure but can also arise from a firm’s superiority. The 
recent stream of literature on divestiture suggests that 
divestiture does not emerge just from responding to the 
internal threats faced by a firm, but is also a proactive 
strategic tool to respond to either external opportunities 
or internal threats [14].  
 
Many opportunities remain for the generalization and 
extension of our findings to other contexts. Our empirical 
results are based on an exploratory case study of an 
Italian firm. In other parts of the world, the relation 
between divestiture and innovation might be different, 
and hence the magnitude of the effect could be affected 
by different institutional conditions.  
 
Moreover, we focused our study on the pharmaceutical 
industry. Future research could start from these 
preliminary findings and investigate how industry-
related characteristics can influence the role of divestiture 
in innovation strategy, testing our positive view in 
different industries. Finally, it would be interesting to test 
our insights on a panel dataset. Collecting data over time, 
it is possible to obtain multiple observations for each 
company. In such a case, a casual inference between 
divestiture and innovation could be made and more 
robust evidence could be obtained. 
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